Baseline lactate dehydrogenase (LDH) and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with everolimus (EVE) versus sunitinib (SUN): Predictive biomarker analysis from the RECORD-3 trial Meeting Abstract

  

Authors:	Voss, M. H.; Chen, D.; Marker, M.; Knox, J.; Hsieh, J.; Voi, M.; Motzer, R. J.
Abstract Title:	Baseline lactate dehydrogenase (LDH) and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with everolimus (EVE) versus sunitinib (SUN): Predictive biomarker analysis from the RECORD-3 trial
Meeting Title:	52nd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	34
Issue:	15 Suppl.
Meeting Dates:	2016 Jun 3-7
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2016-05-20
Language:	English
ACCESSION:	WOS:000404711500081
DOI:	10.1200/JCO.2016.34.15_suppl.e16118
PROVIDER:	wos
Notes:	Meeting Abstract: e16118 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/155126